Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present at the 35th Annual Piper Sandler Healthcare Conference. The presentation by CEO Guido Baechler and CFO Bill Caragol will be available for live viewing and post-event webcast. The conference aims to bring together industry executives, investors, and professionals to explore critical trends and identify impactful leaders in the healthcare market. Baechler and Caragol will also be available for 1-on-1 meetings with investors.

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35^th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, Chief Financial Officer, will be available to view live and post event via webcast by registering at the following link.

Viewers will be able to watch the full presentation live at 8.50am EST on Wednesday, November 29, 2023 and it will be available via the same link for 90 days.

Taking place in New York, NY, USA from 28-30 November, 2023, the conference will bring together key industry executives, investors and Piper Sandler professionals to provide multiple perspectives, investigate critical trends and identify the impactful leaders in the healthcare market.

Guido Baechler and Bill Caragol will be available for 1-on-1 meetings with investors after the presentation and throughout the day.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed N.V.  
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert^®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert^® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.

For media inquiries -
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

In the U.S.:
Josh Stanbury
+1 416 628 7441
josh@sjspr.co

For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

When will Mainz Biomed present at the 35th Annual Piper Sandler Healthcare Conference?

Mainz Biomed will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023, at 8:50am EST.

Where can I view the presentation by Mainz Biomed?

The presentation will be available for live viewing and post-event webcast. Viewers can register to watch it via webcast at the provided link.

Who will be delivering the presentation at the conference?

The presentation will be delivered by CEO Guido Baechler and CFO Bill Caragol.

What is the focus of Mainz Biomed as a company?

Mainz Biomed is a molecular genetics diagnostic company specializing in the early detection of cancer.

Where can I find more information for investors?

For more information for investors, please visit Mainz Biomed's official website at mainzbiomed.com/investors/.